“The treatment of the first patient in the miR-AGE trial is an important milestone for Abivax,” added Philippe Pouletty, M.D., Chairman of the Board of Abivax and CEO of Truffle Capital
First patient treated in “miR-AGE” trial at University Hospital Center in Nice (CHU Nice)
50 study sites and 1,034 high-risk patients to participate in the European and Latin American placebo-controlled trial
ABX464 works via unique triple action: antiviral, anti-inflammatory and tissue repair
Easy, once daily oral administration allows inclusion of hospitalized as well as non-hospitalized COVID-19 patients
Results from this study expected by year-end
